共 23 条
[1]
The Effect of Hyperhomocysteinemia on Motor Symptoms, Cognitive Status, and Vascular Risk in Patients with Parkinson’s Disease[J] . Bilge Kocer,Hayat Guven,Isik Conkbayir,Selim Selcuk Comoglu,Sennur Delibas,Ivan Bodis-Wollner.Parkinson’s Disease . 2016
[4]
Dyskinesia in Parkinson's disease: mechanisms and current non‐pharmacological interventions[J] . Rolf Heumann,Rosario Moratalla,Maria Trinidad Herrero,Koushik Chakrabarty,René Drucker‐Colín,Jose Ruben Garcia‐Montes,Nicola Simola,Micaela Morelli.J. Neurochem. . 2014 (4)
[5]
Effects of l -tryptophan on l -DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson's disease[J] . Wai Kin D. Ko,Qin Li,Erwan Bezard.Neuroscience Letters . 2014
[6]
Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: a meta‐analysis of levodopa‐controlled trials[J] . M. Chondrogiorgi,A. Tatsioni,H. Reichmann,S. Konitsiotis.Eur J Neurol . 2014 (3)
[7]
Investigating the molecular mechanisms of L-DOPA-induced dyskinesia in the mouse[J] . Veronica Francardo,M. Angela Cenci.Parkinsonism and Related Disorders . 2014
[8]
Levodopa, vitamins, ageing and the neuropathy of Parkinson’s disease[J] . Yusuf A. Rajabally,Jean Martey.Journal of Neurology . 2013 (11)
[9]
Receptor Heteromers in Parkinsonμs Disease and L-DOPA-Induced Dyskinesia[J] . Chiara Fiorentini,Paola Savoia,Daria Savoldi,Cristina Missale.CNS & Neurological Disorders - Drug Targets . 2013 (8)
[10]
Wearing Off, Dyskinesia, and the Use of Continuous Drug Delivery in Parkinson’s Disease[J] . Peter Jenner.Neurologic Clinics . 2013